🇺🇸 FDA
Pipeline program

REGN4461

R4461-PLD-20100

Phase 2 small_molecule terminated

Quick answer

REGN4461 for Familial Partial Lipodystrophy is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Familial Partial Lipodystrophy
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials